Related references
Note: Only part of the references are listed.Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia
Biao Wang et al.
SCIENTIFIC REPORTS (2020)
The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML
Jennifer B. Dunlap et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Nucleophosmin in leukemia: Consequences of anchor loss
Barbora Brodska et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2019)
Acute Myeloid Leukemia, Version 3.2019
Martin S. Tallman et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia
Bijan Moshaver et al.
LEUKEMIA RESEARCH (2019)
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
Prajwal C. Boddu et al.
CANCER (2019)
Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1
Yi Zhou et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2019)
A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome
Emily F. Mason et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
When the good go bad: Mutant NPM1 in acute myeloid leukemia
Preethi Kunchala et al.
BLOOD REVIEWS (2018)
Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia
Song-Bai Liu et al.
CANCER SCIENCE (2018)
The impact of age, NPM1(mut), and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia
Jasmin Straube et al.
BLOOD (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio
J. Versluis et al.
LEUKEMIA (2017)
Biological and clinical consequences of NPM1 mutations in AML
E. M. Heath et al.
LEUKEMIA (2017)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia
Tamara Alpermann et al.
HAEMATOLOGICA (2016)
Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia
S. Wakita et al.
LEUKEMIA (2016)
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia
Tamara Alpermann et al.
HAEMATOLOGICA (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered
Wendelien Zeijlemaker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Prognostic Significance of NPM1 Mutations in the Absence of FLT3-Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
Fabiana Ostronoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3
Anar Damdinsuren et al.
LEUKEMIA RESEARCH (2015)
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia
Luca Maurillo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD- mutations
Xiaopeng Tian et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Bob Lowenberg
BLOOD (2013)
Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis
Chien-Yuan Chen et al.
BMC CANCER (2013)
CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia
Harry Dang et al.
HUMAN PATHOLOGY (2013)
Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next-Generation Sequencing Data
David H. Spencer et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics
Wen-Chien Chou et al.
BLOOD (2011)
F1t3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner
Timothy S. Pardee et al.
EXPERIMENTAL HEMATOLOGY (2011)
TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Klaus H. Metzeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression
Guilan Jin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myelold leukemia cells
Eystein Oveland et al.
LEUKEMIA RESEARCH (2009)
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine:: A Cancer and Leukemia Group B study
Andreas Neubauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Aberrant marker expression patterns on the CD34+CD38-stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission
A. van Rhenen et al.
LEUKEMIA (2007)
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
T Suzuki et al.
BLOOD (2005)
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.
B Falini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
